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INTRODUCTION
Interleukin (IL)-2 is a cytokine that has antitumor activ-
ity in selected solid tumors. Based on data suggesting that
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ABSTRACT
In this pilot trial of interleukin (IL)-2–treated autologous bone marrow (BM) and peripheral stem cell (PSC)–sup-
ported high-dose chemoradiotherapy, we report 36 patients with poor-prognosis leukemia and lymphoma who
received BM and/or granulocyte colony-stimulating factor (G-CSF)–mobilized autologous PSCs that had been
exposed to IL-2 for 24 hours ex vivo. Patients then received IL-2 by low-dose continuous intravenous (i.v.) infusion
until hematologic reconstitution and then by intermediate-dose continuous i.v. infusion for six 2-week maintenance
cycles given at 1-month intervals. The median Day to neutrophils over 500/mL was 22 with BM and 10 with PSCs 
(p 5 0.01). The median Day to platelets .20,000/mL was 50 for BM and 25 for PSCs, and to platelets .50,000/mL
was 138 for BM and 34 for PSCs (p not significant). After the first three patients received IL-2 at 2 mIU ? m22 ? day21
and had slow reconstitution, four patients were treated without IL-2 until the maintenance phase following recon-
stitution. The remaining 29 patients received the initial “post-infusion” IL-2 at 1 mIU ? m22 ? day21. Toxicities asso-
ciated with the infusion of IL-2–activated cells consisted of chills and fever in about one-half of the patients and
transient hypotension in 12%. Low-dose IL-2 by continuous i.v. infusion in the early posttransplant period was asso-
ciated with exacerbation of fever, diarrhea, and altered mental status in a minority of patients. The major dose-limit-
ing toxicities of maintenance IL-2 were fever, fatigue, gastrointestinal symptoms, skin rash, and dyspnea. Among 24
lymphoma patients, nine are in continuous complete remission (CCR) from 18–48 months, and 15 have died (12 due
to relapse and three of therapy-related toxicities). Of 12 acute leukemia patients, two with acute lymphoblastic
leukemia (ALL) are in CCR at 38 and 43 months, and one patient who was in cytogenetic but not molecular remis-
sion of Philadelphia chromosome–positive ALL died of progressive leukemia at Day 108. Three of nine with myeloid
leukemia are in CCR at 21, 46, and 53 months; one is in hematologic and cytogenetic remission of acute promyelo-
cytic leukemia at 55 months with multiple new cytogenetic abnormalities; one is alive at 54 months with pancytope-
nia after incomplete hematologic recovery followed by multiple new cytogenetic abnormalities (myelodysplasia); and
one had an unrelated donor transplant after relapsing 4 months following protocol therapy. One myeloid leukemia
patient remains without evidence of relapse, but is transfusion-dependent at 15 months following transplant.
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the activation of natural killer (NK) or cytotoxic T lympho-
cytes (CTL) or both is also active against leukemia and lym-
phoma cells, IL-2–based therapies have also been under
intense investigation for hematologic malignancies.
Patients with acute leukemia in relapse or beyond first
remission are rarely cured except by allogeneic bone mar-
row transplantation (BMT). Patients with lymphoma who
are, on average, older than adults with acute leukemia have
rarely been treated with allogeneic BMT due to the
markedly increased incidence of graft-vs.-host disease
(GVHD) in older patients and the extensive prior exposure
to systemic therapies, which limits both the tolerance and
the antitumor activity of the conditioning regimens [1].
High relapse rates following syngeneic BMT and analyses of
the prognostic variables associated with relapse in patients
with acute and chronic myelogenous leukemia undergoing
allogeneic BMT have demonstrated that a graft-vs.-
leukemia (GVL) effect contributes to the cure of these
patients. However, only about one-third of patients with
acute leukemia and a much smaller percentage of lymphoma
patients have a suitable transplant donor and are candidates
for allogeneic transplantation. Furthermore, pooled results
in patients with intermediate-grade lymphoma have failed to
show an overall relapse-free or survival benefit from allo-
geneic over autologous transplant [2]. The role of allogeneic
vs. unmanipulated or manipulated autologous transplants
for low-grade lymphoma is currently under investigation.
IL-2 has been administered to patients following recov-
ery from autologous transplant in an effort to reproduce the
graft-vs.-malignancy effect. Histologic evidence of a graft-
vs.-host–like phenomenon has been reported in patients
receiving IL-2 following autologous bone marrow (BM) or
stem cell transplant as well as in those treated with combina-
tions of low-dose cyclosporin A with or without an interfer-
on (IFN) [3–6].
We recently reported a series of laboratory investiga-
tions that support the hypothesis that IL-2–activated human
BM and peripheral blood mononuclear cells (PBMC) can be
exploited as a source of cytotoxic effector cells capable of
eradicating residual leukemia while preserving hemato-
poietic reconstitutive potential [7]. The advantages of such
an approach include the potential for direct exposure of
optimal effector cell populations to IL-2 and target determi-
nants, and the very high ratio of effector to target cells in
the product, which is necessary to provide an immunologic
purging of residual malignant cells. Complete or near-com-
plete eradication of chemotherapy-sensitive and -resistant
contaminating cells of several tumor cell lines was demon-
strated when BM was incubated with IL-2–activated PBMC
under conditions that did not significantly suppress hemato-
poiesis. Optimal cytotoxicity occurred with prolonged con-
tinuous exposures to IL-2, and re-exposure of the 24-hour
IL-2–activated cells to IL-2 after a 1- or 2-week IL-2 with-
drawal was associated with full recovery of cytotoxicity in
vitro. Overall recovery of viable cells was .100%, possibly
due to a proliferative effect of the prolonged IL-2 exposure
on lymphoid cells such as T cells and NK cells.
The present pilot study was designed to test the feasibil-
ity of ex vivo treatment of BM and/or PBSC with IL-2 for
autologous transplantation following ablative therapy in
patients with poor-prognosis acute leukemia or lymphoma.
Because IL-2 treatment may be associated with severe
multi-organ toxicities when administered early following
autologous BMT, a very low dose of IL-2 was used during
the initial post-infusion period. The initial dose was select-
ed based on data from the Dana-Farber Cancer Center [8],
the University of Washington [9], and the University of
Minnesota [10], demonstrating that continuous intravenous
(i.v.) infusions of 0.6–9 mIU/m2 for periods of 3–21 days
could be tolerated without excess toxicity. After hematolog-
ic reconstitution, a higher dose of IL-2 was administered
for six maintenance cycles (5 days of treatment, 2 days of
rest, 5 days of treatment, and 14 days of rest), repeated
every 28 days.
After our initial experience with 20 patients who
received IL-2–activated marrow with or without supple-
mental peripheral stem cells, we studied 16 additional
patients whose sole source of hematopoietic support was
peripheral stem cells activated by the same technique with
IL-2. This allowed us to explore the safety and feasibility of
using peripheral blood–derived cells, which have been
shown to reconstitute earlier than autologous BM [11] and
may contain similar precursors to CTL or lymphokine-acti-
vated killer (LAK) cells.
MATERIALS AND METHODS
Eligibility criteria
Patient eligibility criteria for this study included age
$16 years, acute leukemia in first remission if associated
with high-risk features (prolonged therapy required to
achieve remission, poor-risk cytogenetics such as Philadel-
phia chromosome [Ph]), and beyond first remission if the
bone marrow demonstrated remission histology and normal
cytogenetics. Persistence of a molecular marker associated
with the disease was allowed. Patients with Hodgkin’s dis-
ease or non-Hodgkin’s lymphoma were not required to be
in remission, but were required to have a normal morpho-
logic and cytogenetic BM examination before protocol
enrollment.
The laboratory requirements were absolute granulocytes
$1000/mL, total white blood count $3500/mL, platelet
count $100,000/mL, bilirubin #1.5 mg/dL, transaminases
no higher than twice the upper limits of normal, hepatitis B
surface antigen and HIV antibody negative, serum creatinine
#2.0 mg/dL, or creatinine clearance .70 mL/minute.
Organ function requirements were a normal stress thalli-
um test in patients over the age of 40 (patients under 40 were
screened with a stress test without thallium imaging), a left
ventricular ejection fraction of at least 55% by radionuclide
scan, forced expiratory volume (FEV1) $2 liters or 75% of
that predicted with no evidence of obstructive abnormalities
of pulmonary function on standard spirometry, and resting
room air PaO2 $75 mmHg.
Patients were excluded if they had current evidence of
central nervous system involvement with malignancy (found
by physical exam, cerebrospinal fluid cytology, computer-
ized tomography, or magnetic resonance imaging), history
of cardiac or pulmonary disease, history of seizures, concur-
rent or expected need for therapy with corticosteroids,
active connective tissue disease, pleural effusion, pericardial
effusion, ascites, pregnancy, or lactation.
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The protocol was approved by the institutional review
boards at the City of Hope National Medical Center and
the M.D. Anderson Cancer Center, and voluntary written
informed consent was obtained from each patient before
beginning protocol treatment.
Bone marrow harvest and activation
Bone marrow and stem cell harvest and cryopreserva-
tion were performed according to institutional standard
techniques. The initial step consisted of concentrating the
mononuclear cells and depleting red blood cells and granu-
locytes. The final concentration of BM mononuclear cells
(BMMC) in 100-mL cryopreservation bags was between 3.0
and 7.03108/mL in calcium, magnesium-free phosphate-
buffered saline ([PBS]; #310-4190AG, Gibco Life Technolo-
gies, Grand Island, NY). The final concentration of
dimethyl sulfoxide (#88-854, Research Industries, Salt Lake
City, UT) was 10% and human albumin was 2.5% (Alpha
Therapeutics, Los Angeles, CA).
Patients in the initial BM cohort underwent supplemen-
tary leukapheresis sufficient to provide a total number of
CD341 cells (Becton-Dickinson, Mountain View, CA) of at
least 63106/kg body weight when the marrow product and
stem cell product were added together. Based on our prior
studies [7] and unpublished observations, we anticipated a
maximum cell loss of 50% from harvest to infusion, so the
target number for collection was chosen to provide
23106/kg CD341 cells at the time of infusion and to store
the same number of cells for backup infusion without IL-2
activation in the event of delayed hematologic reconstitu-
tion. After the first 20 patients were entered into this proto-
col, we studied 16 additional patients using PSCs alone as
the source of hematopoietic stem cells for both IL-2 activa-
tion and as the backup product.
For all patients undergoing stem cell collection, mobi-
lization with granulocyte colony-stimulating factor (G-CSF)
at 10 mg ? kg21 ? day21 was given for 4 days preceding and
throughout the daily apheresis procedure. Preparation of
the stem cell product for cryopreservation was performed
exactly as detailed for the BM, except that the final MC con-
centration was between 1 and 33108/mL.
On Day 21, the designated cryopreserved product was
thawed rapidly at 37–398C water bath and recombinant
human DNase type IIS (#4513, Sigma, St. Louis, MO) was
added at a final concentration of 0.2 mg/mL during the thaw.
The product was then transferred to tissue culture bags
(#4R2113, Fenwall, Baxter Healthcare, Deerfield, IL), and
BMMC were diluted to a concentration of 1.5–33106/mL
(or PSC to a concentration of 5–103106/mL) in RPMI-1640
(for adoptive immunotherapy procedures, BioWhittaker,
Walkersville, MD) with the following additives at the final
concentrations specified: L-glutamine, 2 mM; b-mercap-
toethanol, 53105 M; gentamicin, 0.05 mg/mL; heparin, 50
U/mL; IL-2 (Chiron, Emeryville, CA), 6000 IU/mL; and
autologous plasma (collected during apheresis) or ABO-com-
patible plasma, 10%. Cells were incubated 18–24 hours in a
5% CO2 incubator at 378C. Before infusion, samples were
confirmed to be free of bacterial contamination by Gram’s
stain and to contain ,5 endotoxin units/mL by the limulus
amebocyte assay (BioWhittaker). The contents of each incu-
bation bag were then combined, washed in the cell separator
to concentrate the cells, and washed once with normal saline
containing 5% albumin. The final product was resuspended
in 150–200 mL of normal saline with 5% albumin for infu-
sion into the patient. Each patient was premedicated with
25–50 mg of diphenhydramine i.v. and 650–1000 mg of
acetaminophen orally.
Treatment
The conditioning regimens were those in standard use
at the participating institutions and are listed in Table 1.
Supportive care
Supportive care of the patients following reinfusion of
the IL-2–treated cell product was in accordance with previ-
ously published standard practice guidelines for the care of
autologous BMT patients at the City of Hope and the M.D.
Anderson Cancer Center [12–14].
IL-2 therapy
IL-2 was started 24 hours after the infusion of autolo-
gous BM or stem cells or both. The starting IL-2 dose was 2
mIU ? m22 ? day21 by continuous i.v. infusion to be contin-
ued for at least 21 days and until the absolute neutrophil
count (ANC) reached $500/mL. After two of the first three
patients appeared to have delayed hematologic reconstitution
(28, 34, and 38 days to reach ANC $500/mL), four patients
were treated without IL-2 following the cell infusion to con-
firm the adequacy of engraftment of the IL-2–activated
product in the absence of systemic IL-2. These patients
began maintenance after meeting the same reconstitution
criteria used for the entire protocol population. Subsequent-
ly, the protocol was amended so that the post-infusion IL-2
dose was 1 mIU ? m22 ? day21 and all patients received i.v. G-
CSF at 5 g ? kg21 ? day21 from Day 1 until reaching an ANC
$1500/mL. Glucocorticoid therapy was to be strictly avoid-
ed, except in the event of a life-threatening emergency. After
a 2-day rest period, which could be extended to allow for
recovery from constitutional toxicities and to assure adequate
oral intake, patients received the first of six planned cycles of
maintenance IL-2, consisting of 6 mIU ? m22 ? day21 by con-
tinuous i.v. infusion for 5 days followed by 2 days of rest and




A consisted of fractionated total-body irradiation (FTBI), 1200 cGy in 10
120-cGy fractions from Days 28 through 25, which was followed by etopo-
side (VP-16), 60 mg/kg on Day 24, and cyclophosphamide, 100 mg/kg on
Day 22. Mesna, 40 mg/kg, was administered as a uroprotectant just before
cyclophosphamide (CTX) and repeated every 3 hours until 21 hours after the
CTX. For all FTBI patients, lung shielding was provided at 50% of the total
dose.
B consisted of thiotepa, 250 mg · m22 · day21 on Days 28 and 27, which was
followed by busulfan (BU), 1 mg/kg orally every 6 hours for a total of 10 doses
from Days 26 through 24, and CTX, 60 mg · kg21 · day21 on Days 23 and
22. Mesna, 10 mg/kg, was given just before CTX and every 4 hours until 20
hours after the last dose of CTX.
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another 5 days of therapy and 14 days of rest. In general, the
first of these maintenance cycles was begun in the hospital
and further therapy was given at home via a home infusion
pump with physician evaluation of the patient on at least the
1st and 5th day of each half cycle of maintenance IL-2.
Strict rules for the management of IL-2 toxicities and
dose adjustments during the period of low-dose IL-2
administration following activated cell infusion and before
hematologic reconstitution could not be provided, since the
clinical and laboratory complications of IL-2 therapy are
often indistinguishable from those of high-dose condition-
ing therapy and prolonged pancytopenia. The general
guidelines provided for the temporary withholding or dose-
reduction (by decrements of 25, 50, or 75% of the starting
dose) of IL-2 in the event of serious toxicities thought to be
exacerbated or due to IL-2. Treatment could be resumed or
dose-incremented upon resolution of these toxicities.
Data analysis
The NCI Common Toxicity Grading Criteria were used
for the assessment of IL-2 toxicities, and guidelines for
maintenance therapy following hematologic recovery as
defined above were used. IL-2 was to be withheld for any
serious organ toxicity that was not easily managed with stan-
dard supportive care, such as antiemetics, antipyretics, and
i.v. fluids, or for any medical complication of the transplant
to which IL-2 was judged to be contributing. If such toxicity
resolved within 72 hours and was not considered life-threat-
ening or attributable to IL-2, then the IL-2 could be
resumed at 50% of the original dose. Recurrence of similar
toxicities was an indication for the discontinuation of IL-2.
The Kaplan-Meier estimate was used to calculate overall
and relapse-free survival.
The mean number of CD341 cells per kilogram remain-
ing after cryopreservation and thaw and the percentage of
CD341 cell recovery following IL-2 incubation were com-
pared for BM and PSCs using the Student’s t-test and the
Wilcoxon rank-sum test. Times to recovery for neutrophils
and nontransfused platelet counts .50,000/mL were com-
pared with those from patients receiving BM only vs. PSC
only, using the log-rank test. The significance level was set
at alpha 5 0.05 and all tests were two-sided.
RESULTS
Patient characteristics
Thirty-six patients (12 women and 24 men with a medi-
an age of 33 years [range 17–59 years]) were entered into this
study between December 1993 and August 1997. All patients
were eligible for the study and evaluable for initial reconsti-
tution and toxicity data. Table 2 shows patient characteristics
and treatment regimens. Twenty-three patients had non-
Hodgkin’s lymphoma, consisting of B-cell lymphomas of
intermediate- or high-grade subtypes in 22 patients and T-
cell lymphoblastic lymphoma in one, and one patient had
Hodgkin’s disease. For the non-Hodgkin’s lymphoma
patients, their disease status at study entry was as follows:
two patients in first complete remission, three in first partial
remission, 12 induction failures (defined as failure to achieve
complete or partial remission with first-line and salvage ther-
apy), four in partial or complete remission following treat-
ment of relapse, and two in untested or unresponsive relapse.
The patient with Hodgkin’s disease was also an induction
failure. Twelve patients had acute leukemia, three lym-
phoblastic, and nine myeloid. Of the myeloid leukemia
patients, two were in third remission, four were in second,
and three were in first (one of these patients had an unsus-
pected isolated central nervous system relapse detected upon
study entry, which was treated with intrathecal chemo-
therapy before the conditioning regimen). Indications for
protocol therapy in first remission in these three patients was
a prolonged induction therapy to achieve a first remission
(two patients) and a treating physician’s judgment of high-
risk (one patient). Of the lymphoblastic leukemia patients,
one was in second remission and two were in first remission
(one with Ph1 acute lymphoblastic leukemia [ALL] that had
become cytogenetically negative but with persistent poly-
merase chain reaction (PCR)-positivity for the bcr-abl
translocation). Conditioning regimens and number of
patients treated with each regimen are shown in Table 1.
Hematologic reconstitution
Following mononuclear cell preparation, cryopreserva-
tion, thaw, and IL-2 activation, the median number of
CD341 cells infused into the 14 patients (data available on 13)
who received only BM was 1.06 (range 0.12–4.77) 3106/kg.
The median number of CD341 cells infused into the 16
patients who received only PSCs was 4.14 (range 0.13–28.7)
3106/kg. For the six patients who received cells from both
sources, the median number of CD341 cells infused was 1.7
(range 0.35–4.21) 3106/kg. There was a statistically higher
Table 2. Diagnosis and remission status at protocol entrya
Remission status Number of 
Disease (n) at entry patients
Lymphoma (24)
B cell, intermediate
high-grade (22) CR 1 2
PR 1 3
IFb 12
Beyond first remission 3
Otherc 2
T lymphoblastic (1) CR 1 1
Hodgkin’s disease (1) IF 1
Acute Leukemia (12)
Myeloid CR 3 2
Myeloid CR 2 4
Myeloid CR 1d,e 3
Lymphoid CR 2 1
Lymphoid CR 1 2
aData are from 36 patients (12 female, 24 male) with a mean age of 33 years
(range 17–59 years).
bInduction failure, failure to achieve complete remission (CR) or durable par-
tial remission (PR) with prior therapy.
cOther, untested or chemoresistant relapse.
dOne of these patients had central nervous system leukemia at the time of pro-
tocol entry.
eIndications for protocol therapy in first remission: extra-medullary leukemia
(one patient), repeat cycles of induction therapy (one patient), and physician
judgment.
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yield of CD341 cells following activation of PSCs than BM
(mean 6 standard deviation: 55 6 24% for PSC vs. 34 6
21% for BM, p , 0.01 by Wilcoxon rank-sum test).
Hematopoietic recovery data are shown in Table 3. The
median Day to neutrophils over 500/mL was 22 for the 14
patients receiving BM alone and 10 for the 16 patients
receiving PSC alone (p 5 0.01), demonstrating a significant
shortening of neutrophil reconstitution time with the use of
the PSC product. The median Day to platelets .20,000/mL
was 50 for BM and 25 for PSC and to platelets .50,000/mL
was 138 for BM alone and 34 for PSC alone, showing a non-
significant trend to earlier platelet recovery with the PSC
product. The number of patients receiving BM plus PSCs
(six patients) was insufficient for meaningful comparison of
recovery times. Two patients, both in the BM alone group,
received the backup BM product because of delayed recov-
ery. The first patient had received 0.63106/kg CD341 cells
and was given the backup PSCs containing 0.513106/kg
CD341 cells at Day 21 during an episode of hepatic dysfunc-
tion and sepsis, which led to the discontinuation of IL-2.
This patient had converted to hepatitis C seropositivity just
before transplant. He also developed multiple new cytoge-
netic abnormalities that were discovered at the Day 480 BM
evaluation and clinical myelodyplasia with failure to achieve
sustained megakaryopoiesis at .1 year posttransplant. The
second patient had persistently positive bcr-abl gene translo-
cation by polymerase chain reaction analysis despite achiev-
ing a cytogenetic second CR of Ph1 ALL. She received
4.83106/kg CD341 cells initially and the backup product,
containing 6.673106/kg CD341 cells, was infused on Day
30. This patient never achieved hematologic recovery and
died due to leukemic relapse on Day 108. We believe the IL-
2–activated product may have contained clonal leukemic
cells accounting for the apparent discrepancy between the
high CD341 yield and the poor reconstitution/early relapse
experienced by this patient.
One additional patient, a 27-year-old woman who has
remained in CCR for .45 months since protocol therapy,
developed delayed engraftment failure characterized by pro-
gressive pancytopenia with a hypoplastic, cytogenetically nor-
mal marrow starting at 36 months following infusion of the
IL-2–activated BMMC containing 1.333106/kg CD341 cells.
This patient was one of the four individuals treated without
post-infusion IL-2 by protocol, and her reconstitution had
been similar to that of the other patients receiving BM alone,
with ANC reaching $500/mL by Day 21 and $1000/mL by
Day 22 and platelets recovering to $20,000/mL and
$50,000/mL. She had received 38% of the maintenance IL-2,
which was discontinued because of interstitial lung disease
attributed to prior and protocol chemotherapy and radiation
to the mediastinum and later resolved. This patient was rein-
fused with her unmanipulated backup BMMC product and
experienced an improvement in blood counts.
Toxicities of IL-2
Toxicities associated with the infusion of IL-2–activated
cells consisted of chills or fever or both and hypoxia in 16
patients (44%). Three patients (8%) had hypotension
requiring vasopressor therapy transiently, and one patient
had severe chest pressure with nausea and diaphoresis for
which glucocorticoid therapy was administered. Eight
patients inadvertently received hydrocortisone premedica-
tion for the activated cell infusion; there was no apparent
difference in the incidence of infusion reactions between
these patients and the entire study population.
The specific toxicities due to IL-2 therapy in the early
posttransplant phase could not readily be distinguished from
those that were expected from the conditioning regimens and
the hypoplastic period. Apparent exacerbation of fever, diar-
rhea, rash, altered mental status, and the sepsis syndrome were
potentially attributable to the low-dose IL-2 infusion and gen-
erally managed by the interruption of or decreasing the infu-
sion dose. There was no episode of life-threatening cardiac,
pulmonary, renal, hepatic, gastrointestinal, or neurologic toxi-
city due uniquely to IL-2. Among the five patients who suc-
cumbed to regimen-related toxicities without evidence of dis-
ease relapse, two died of pulmonary complications during the
hypoplastic period. Both of these patients had been subjected
to extensive prior therapy. Two other patients died of delayed
cardiopulmonary problems with a possible viral etiology con-
tributing to their death. One patient died of septic complica-
tions of a biopsy-confirmed autologous GVHD syndrome,
predominantly involving the skin.
An integrated measure of the toxicities of cytokine thera-
py, which is difficult to quantitate on standard toxicity scales
particularly in the posttransplant setting, is the percent of
planned IL-2 that could be safely administered. The median
post-infusion IL-2 exposure was 74% (range 19–100%). Ten
of 32 patients (31%) received over 90% of the planned dose.
The median interval between the completion of post-
infusion IL-2 and the initiation of maintenance IL-2 was 7
days (range 248 days) for the 22 patients who were able to
begin maintenance therapy. Fourteen patients could not be
evaluated for the toxicities of maintenance IL-2: four did
Table 3. Hematologic recovery (days post-infusion)
ANC $500/mL ANC $1000/mL Plts $20,000/mL Plts $50,000/mL
BM only (n514) 22a 27 50 138
(11–38) (13–46) (18–486) (27–243)
BM 1 PSC (n56) 12 14 20 44
(10–21) (11–24) (12–47) (18–242)
PSC only (n516) 10a 11 25 34
(8–43) (9–60) (7–271) (9–390)
ap 5 0.01 by log-rank test; patients receiving BM only vs. those receiving PSC only.
The number of patients receiving BM plus PSC (six patients) was insufficient for meaningful comparison of recovery times.
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not receive post-infusion IL-2 by protocol amendment, as
described above; two had delayed hematopoietic recovery,
one of whom also experienced a flare of hepatitis C; and two
died early due to regimen-related toxicities. One patient
died early of lymphoma relapse, one died of leukemia
relapse, and four (two leukemia and two lymphoma patients)
refused maintenance IL-2.
For the analysis of toxicities due to IL-2 administration
in the maintenance phase (following hematopoietic recon-
stitution), the NCI Common Toxicity scale was used. The
guidelines for dose adjustments were flexible, however, so
we report the dose-limiting toxicities along with the percent
of planned IL-2 administered in this phase of therapy. The
median IL-2 administered during the maintenance phase for
the 22 patients who did not relapse prior to the planned
completion of maintenance was 33% (range 8–100%),
which represents an intent-to-treat and includes patient
refusals (patients who were medically eligible to proceed to
maintenance IL-2) and those whose treatment was withheld
due to regimen-related toxicities. For all patients who began
maintenance IL-2 and did not relapse early, the median
received was 66% of planned (range 8–100%), and six of 21
patients (28%) received over 90% of the planned mainte-
nance IL-2. The dose-limiting toxicities of maintenance IL-
2 were fever, fatigue, gastrointestinal symptoms, skin rash,
dyspnea, and hypotension.
Treatment and results of therapy
Among 24 lymphoma patients, nine are in CCR from 18
to 48 months and 15 have died (12 due to relapse and three
to therapy-related complications). Of 12 acute leukemia
patients, two with ALL are in CCR at 38 and 43 months
and one patient, who was in cytogenetic remission of Ph1
ALL, but whose marrow was persistently positive for the
bcr-abl translocation, died at Day 108 of progressive
leukemia. Three of nine with myeloid leukemia are in CCR
at 21, 46, and 53 months, one is in hematologic and cytoge-
netic remission of acute promyelocytic leukemia at 58
months with multiple new cytogenetic abnormalities, one is
alive at 54 months with pancytopenia after incomplete
hematologic recovery followed at Day 480 by multiple new
cytogenetic abnormalities (myelodysplasia), and one had an
unrelated donor transplant after relapsing 4 months follow-
ing protocol therapy. The two patients who died of therapy-
related complications were described above. One myeloid
leukemia patient remains without evidence of relapse, but is
transfusion-dependent at 151 months following protocol
therapy; this patient had a transient autologous graft-vs.-
host syndrome of skin (biopsy-proven) and liver. The
CD341 cell number infused into this patient was only
0.133106/kg.
The Kaplan-Meier plots of relapse-free and overall sur-
vival are shown in Figures 1 and 2.
DISCUSSION
Relapse of the underlying malignancy is the major cause
of treatment failure after autologous BMT or PSCT. New
strategies are needed to eradicate therapy-resistant residual
disease from the stem cell product and to more effectively
Figure 1. Kaplan-Meier estimate of relapse-free survival
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treat the burden of resistant disease, which remains a source
of relapse in the patient undergoing this form of therapy. To
date, there has been limited success in efforts to purge the
marrow or stem cell product of contaminating clonogenic
cells using separation techniques based on immunopheno-
typic differences between tumor cells and hematopoietic
precursors. The use of chemotherapeutic purging has also
been unsuccessful because of the limited therapeutic ratio of
cytotoxicity against malignant cells vs. stem cells.
Posttransplant immunomodulation and other approaches
to maintenance therapy following BMT or PSCT have also
been of limited value, due in part to the resistance of residual
malignant cells to available treatments. The toxicities of both
chemotherapy and biological agents may be poorly tolerated
in patients who have recently recovered from dose-intensive
therapy. Nevertheless, beneficial immunomodulation may be
achieved at tolerable doses of selected cytokines such as IL-2,
which has been shown to reverse parameters of T-cell dys-
function in patients with malignancy [15].
A syndrome analogous to GVHD occurring in the
autologous transplant setting can be achieved using low
doses of cyclosporine A with or without an IFN [3–6]. IL-2
administered in low doses in the posttransplant setting as
well as IL-2 treatment of the stem cell product may produce
this syndrome that may be associated with improved disease
control. The histologic and clinical changes occurring in the
target organs (skin, liver, and gastrointestinal tract during
acute GVHD, multiple organs and “autoimmune” phenom-
ena in chronic GVHD) are mediated in part by T and B
lymphocytes and NK cells, as well as various antigen-pre-
senting cells in conjunction with cytokines such as IL-2 and
TNF [16]. Systemic IL-2 therapy in patients with malignan-
cy has been reported to cause clinical and histologic phe-
nomena similar to those of acute and even chronic GVHD
[17], which are also mediated by inflammatory cytokines
such as TNF and gamma-IFN [18].
Experimental support for the design of our pilot clinical
study evolved from the preclinical studies of Mazumder et
al., who showed that murine BM exposed to IL-2 contained
cytotoxic effectors including NK and T cells, which could
eradicate tumors from the BM and cure experimental malig-
nancy [19]. Our own studies of IL-2 in artificially contami-
nated marrow demonstrated the antitumor effects of BM-
and PBMC-derived effector cells against both chemo-
therapy-sensitive and -resistant tumor cells, the preservation
of hematopoiesis, and the ability of the IL-2–activated cells
to rapidly recover cytotoxicity despite interruption of the
IL-2 exposure for up to 2 weeks followed by re-exposure to
IL-2 [7]. We subsequently found that LAK cells derived
from PBMC had similar or higher cytotoxicity than IL-
2–activated BMMC from the same individuals (normal
donors for allogeneic BMT [C.W. and K.M., unpublished
observations, 1992]). Because hematologic recovery occurs
sooner following transplantation of autologous G-
CSF–mobilized PSC than autologous BM [11,12], there was
sufficient rationale for the evaluation of IL-2–activated G-
CSF–mobilized PSC in lieu of BM or BM supplemented
with PSCs in a group of patients in this study.
The results of our study demonstrate the feasibility of
activating cryopreserved BM or PSCs or both with IL-2 for
24 hours before its infusion following ablative chemoradio-
therapy. The recovery times for neutrophils and platelets
Figure 2. Kaplan-Meier estimate of overall survival
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using BM alone were comparable with those of autologous
unmanipulated BMT in patients undergoing the same con-
ditioning regimens for acute leukemia and lymphoma [12].
The significant shortening of these recovery times with
added PSC or with PSC alone is also consistent with the
more rapid recovery following PSCT than BMT [11,12].
The toxicities of the low-dose IL-2 infusion in the post-
transplant period were moderate and often indistinguishable
from those of the conditioning agents and the period of
pancytopenia. In most patients, there was little added toxici-
ty attributable to IL-2 (mainly fever and exacerbation of a
septic syndrome without overt organ toxicities), which was
generally not severe enough to require discontinuation of
the low-dose IL-2 infusion during this phase of treatment.
The predominant reason for reducing the dose or interrupt-
ing the IL-2 infusion during this period was fever.
The toxicities of the higher-dose maintenance cycles
were predominantly constitutional, such as fever, fatigue, and
anorexia, but most patients did not suffer toxicities at a level
that required treatment discontinuation for management of
organ dysfunction or symptom relief. IL-2 dose adjustments
were common during the maintenance cycles, however, the
mean IL-2 administration was two-thirds of the planned
total dose for those patients whose IL-2 was not discontin-
ued due to disease relapse before the time required to receive
six cycles of maintenance IL-2. Thus, BM and PSCs from
patients previously treated and at high risk for recurrent
leukemia or lymphoma can be safely exposed to IL-2 without
loss of hematopoietic potential and, thus, potentially provide
an immunologic effect that can be augmented by the use of
prolonged treatment with systemic IL-2.
The data from clinical trials of IL-2–based therapy in
leukemia and in the post-BMT setting were reviewed by Foa
[20] and Sznol and Parkinson [21]. Based on preclinical data
that showed the sensitivity of a variety of leukemic cells to
cytolysis and/or growth inhibition mediated by IL-2–activat-
ed effector cells [22–26] and the lack of potentiation of
leukemic cell growth by direct exposure to IL-2 [27], clinical
trials of systemic IL-2 were initiated in patients with acute
leukemia in relapse. Antileukemic activity was observed in a
small number of patients with marrows containing a limited
number of blasts, but those who were in rapidly progressive
relapse with “packed” bone marrows failed to benefit. Based
on these encouraging results, formal phase II testing of IL-2
in myeloid leukemia has been initiated in a European inter-
group study, and a randomized trial of maintenance IL-2 in
patients in second remission of myeloid leukemia is planned
(G. Meloni, personal communication, 1997).
Several other groups of investigators have piloted an
immunotherapeutic approach to the elimination of “mini-
mal residual disease” in the setting of autologous BMT.
Robinson et al. reported on 22 patients with acute leukemia
in relapse or beyond first remission who underwent autolo-
gous BMT or PSCT using cells which had been harvested
during first complete remission [28]. IL-2 was given by con-
tinuous i.v. infusion after hematologic recovery at doses
ranging from 9 to 12 mIU ? m22 ? day21 for 4–5 days, fol-
lowed 1 week later by a 10-day infusion of 1.6 mIU ? m22 ?
day21. Among 17 patients with AML, four remained in con-
tinuous remission 12–25 months after therapy and four of
five ALL patients were also in remission 15–25 months fol-
lowing treatment [28]. This regimen is currently undergo-
ing evaluation in a randomized study of the Southwest
Oncology Group in which patients with lymphoma under-
going autologous peripheral stem cell transplantion
(aPSCT) are randomized to receive a single cycle of IL-2 vs.
no further therapy.
Blaise et al. reported on 38 patients with acute leukemia,
lymphoma, and Hodgkin’s disease treated with autologous
bone marrow transplantion (aBMT) followed by IL-2 after
reconstitution [29]. IL-2 was administered as five 14-day
cycles of 5 days of IL-2 and 9 days of rest and is given by
continuous i.v. infusion at doses ranging from 12 to 24 mIU ?
m22 ? day21. There was no apparent suppression of hemato-
poietic recovery, and cytolytic activity of PBMC against NK-
sensitive and NK-resistant targets was achieved. Among 18
patients with acute leukemia in first remission, 13 remained
disease-free at 1 year [29]. Bosly et al. also studied the toler-
ance of IL-2 infusions following reconstitution in 19 patients
with lymphoma and solid tumors treated with aBMT [30]. In
this phase I study, 19 patients received four blocks of IL-2
therapy given by continuous i.v. infusion for 4.5- or 5-day
periods separated by a several day recovery period. Doses
ranged from 3 to 24 mIU ? m22 ? day21, but IL-2 toxicities
limited the total exposure to approximately one-half of the
planned therapy at all but the lowest dose level [30].
Most recently, our group has treated patients with acute
myelogenous leukemia in remission with high-dose cytara-
bine (Ara-C) consolidation followed by autologous unmanip-
ulated PSCT and then a two-part IL-2 exposure using the
Seattle regimen [9] following hematologic reconstitution.
Among 38 patients in first complete remission who were
treated with this protocol, five were unable to undergo
aPSCT because of consolidation complications (three) or
insufficient stem cell collection (two). Of the 33 patients
undergoing transplant, 23 recovered sufficiently to receive
IL-2. For the entire transplanted group, the 2-year disease-
free survival probability was 81% (91% for those who
received IL-2) [31]. The results of randomized trials will be
necessary to define the feasibility and value of this approach
in larger groups of patients.
Three groups have attempted to administer low-dose
IL-2 to aBMT patients prior to hematologic recovery. Weis-
dorf et al. treated 14 patients with ALL in remission, start-
ing at Day 1 following conditioning with cyclophosphamide
(CTX) and fractionated total-body irradiation (FTBI) and
reinfusion of autologous BM treated with low-dose 4-
hydroperoxycyclophosphamide and an anti-CD19 immuno-
toxin [10]. Patients were treated at three different dose lev-
els of IL-2 equivalent to 1.5, 3, and 6 mIU ? m22 ? day21 by
continuous i.v. infusion for 96 hours/week for 3 weeks.
Although hematologic recovery was faster than historical
controls, multi-organ toxicity was prohibitive at the two
higher doses and there was no detectable enhancement of
circulating NK or LAK activity at various times post–IL-2
infusion [10].
Heslop et al. administered short i.v. infusions of IL-2 to
patients immediately following myeloablative therapy with
CTX/TBI and autologous unmanipulated BM reinfusion for
hematologic malignancy [32]. Sixteen patients received IL-2
doses equivalent to 0.1–1.4 mIU/m2 over 6 or 24 hours daily
for 3–5 days, which was tolerated without excessive toxicity
KA Margolin et al.
44
over post-aBMT effects. Transient increases in neutrophil
counts occurred during the IL-2 infusions, but overall recon-
stitution was not accelerated. Circulating mononuclear cell
production of IL-3 and GM-CSF was increased during IL-2
infusions when compared with controls [32].
Klingemann administered IL-2 infusions to patients
immediately after autologous BMT for high-risk AML in
first remission, using marrow activated ex vivo with IL-2 in a
long-term culture system [34]. Patients were conditioned
with busulfan and CTX and then received low doses of IL-2
by continuous i.v. infusion for the first 8 days following BM
reinfusion. At doses of 2, 4, or 6 3 105 U ? m22 ? day21 (con-
version factor unknown in IU), all of the planned IL-2 ther-
apy could be administered to all but one patient who devel-
oped atrial fibrillation, hypotension, and renal insufficiency.
The slow hematologic reconstitution was attributed to the
prolonged ex vivo BM incubation. Two patients died from
infection during aplasia [33]. These authors subsequently
demonstrated significant shortening of the time to hemato-
logic recovery when PSC were used instead of BM [33,34].
The potential contribution of immunologic mechanisms
to the control of minimal residual disease in patients with
leukemia and lymphoma is undergoing intense investigation
and is the subject of randomized trials in the United States.
However, the identification of the products of leukemia- or
lymphoma-specific gene translocations and the recent
observation that the leukemic marrow can also be used to
induce dendritic cells capable of presenting antigen to
cytolytic T cells [35] provides a rationale for further study of
this mechanism of immunotherapy. Based on the high fre-
quency and multiple mechanisms of malignant cell “escape”
from immune control, it is likely that optimal elimination of
residual malignant clones will require more than one
immunotherapeutic intervention.
In conclusion, we have demonstrated the feasibility of ex
vivo treatment of autologous BM and blood progenitor cells
with IL-2, resulting in effector cell activation without
impairment of hematopoietic reconstitution, with encourag-
ing results from our clinical series of 36 patients. The techni-
cal demands of our method, however, raise the practical con-
cern that more simple approaches, such as the administration
of IL-2 or other cytokines or both [36] following definitive
therapy [30,37]—and possibly in conjunction with the stem
cell mobilization procedure before chemoradiotherapy—may
provide benefit to a wider population of patients with hema-
tologic malignancy. Controlled trials will be required to eval-
uate the efficacy of this approach or other “purging” meth-
ods vs. unmodified autologous transplants with or without
alternative immunotherapeutic interventions.
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